Top Cardiac Prosthetic Devices Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Cardiac Prosthetic Devices Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Cardiac Prosthetic Devices industry players.

Cardiac Prosthetic Devices Market Competitive Landscape

The global cardiac prosthetic devices market competitive scenario is dominated by Edwards Lifesciences, Medtronic, Abbott Laboratories, and Boston Scientific. These firms operate with innovation, mergers and acquisitions to keep the leadership intact. Edwards Lifesciences leads with research efforts in heart valve technologies, Medtronic continues to expand minimally invasive surgery solutions, and Abbott supplements its product portfolio with strategic acquisitions for a wide offering of advanced cardiac solutions.

The startup ecosystem in the global cardiac prosthetic devices market outlook is expanding fast, with new-age companies launching cutting-edge solutions for heart valve replacement and vascular repair. These startups are developing minimally invasive treatments, bioresorbable technologies, and personalized medicine to enhance patient outcomes. They are leading tremendous R&D breakthroughs, making cardiovascular therapies more affordable, effective, and cost-saving for a larger patient base.

  • Founded in 2015, Xeltis is a medical device startup pioneering bioresorbable cardiac implants. Their flagship product, the Bioabsorbable Heart Valve, is designed to replace damaged heart valves and gradually absorb over time, allowing natural tissue growth. This pioneering technology encourages the body's own natural healing process, without the need for subsequent surgeries and offering long-term, sustainable solutions to valve replacement, particularly for younger patients.
  • Established in 2016, CardioMech focuses on minimally invasive solutions for mitral valve repair. Their CardioMech Mitral Valve Repair System uses a catheter-based procedure to restore valve function without open-heart surgery. The company's breakthrough R&D is aimed at creating a device that improves outcomes for patients with heart valve disease, particularly those at high surgical risk, by offering a safer, less invasive treatment with faster recovery times and reduced complications.

Top Player’s Company Profiles

  • Abbott Laboratories (USA) 
  • Medtronic plc (Ireland) 
  • Boston Scientific Corporation (USA) 
  • Edwards Lifesciences Corporation (USA) 
  • LivaNova PLC (UK) 
  • Biotronik (Germany) 
  • MicroPort Scientific Corporation (China) 
  • Meril Life Sciences Pvt. Ltd. (India) 
  • Lepu Medical Technology Co., Ltd. (China) 
  • CryoLife, Inc. (USA) 
  • AtriCure, Inc. (USA) 
  • Braile Biomedica (Brazil) 
  • Labcor Laboratórios Ltda. (Brazil) 
  • Lifetech Scientific Corporation (China) 
  • Shree Pacetronix Ltd. (India) 
  • TTK Healthcare Ltd. (India) 
  • Colibri Heart Valve LLC (USA) 
  • Berlin Heart GmbH (Germany) 
  • SynCardia Systems LLC (USA) 
  • Venus Medtech (Hangzhou) Inc. (China)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Cardiac Prosthetic Devices Market size was valued at USD 74.03 Billion in 2023 poised to grow from USD 77.53 Billion in 2024 to USD 112.21 Billion by 2032, growing at a CAGR of 4.73% in the forecast period (2025-2032).

The global cardiac prosthetic devices market competitive scenario is dominated by Edwards Lifesciences, Medtronic, Abbott Laboratories, and Boston Scientific. These firms operate with innovation, mergers and acquisitions to keep the leadership intact. Edwards Lifesciences leads with research efforts in heart valve technologies, Medtronic continues to expand minimally invasive surgery solutions, and Abbott supplements its product portfolio with strategic acquisitions for a wide offering of advanced cardiac solutions. 'Edwards Lifesciences (USA)', 'Medtronic (Ireland)', 'Abbott Laboratories (USA)', 'Boston Scientific (USA)', 'CryoLife (USA)', 'Terumo Corporation (Japan)', 'Johnson & Johnson (USA)', 'Sorin Group (Italy)', 'LivaNova (UK)', 'Cardinal Health (USA)', 'Biotronik (Germany)', 'Tendyne (USA)', 'Aortic Medical (USA)', 'Mitsubishi Tanabe Pharma Corporation (Japan)', 'Vascular Solutions (USA)'

The rising incidences of cardiac diseases globally represent one of the biggest drivers in the global cardiac prosthetic devices market growth. As cardiac issues such as heart valve disease and coronary artery diseases rise, more prosthetic devices like heart valves and vascular grafts are required, which translates into greater opportunities for innovation and growth in the market.

Advancements in Minimally Invasive Procedures: The global cardiac prosthetic devices market trends are directing toward minimally invasive procedures, which reduce recovery times and risks. These kinds of devices, for example, transcatheter heart valves and catheter-based repair systems, are getting popular due to smaller incisions and faster recovery time.

What Factors Contribute to North America's Leadership in the Global Cardiac Prosthetic Devices Market?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Cardiac Prosthetic Devices Market
Cardiac Prosthetic Devices Market

Report ID: SQMIG35A3042

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE